The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study.
Robert van Soest
No relevant relationships to disclose
Ellen de Morrée
No relevant relationships to disclose
Liji Shen
Employment or Leadership Position - Sanofi ; Sanofi
Stock Ownership - Sanofi
Ian Tannock
Consultant or Advisory Role - Sanofi ; Sanofi
Honoraria - Sanofi
Research Funding - Sanofi ; Sanofi
Mario A. Eisenberger
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi
Ronald De Wit
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Sanofi